Vor Biopharma reported earnings of -$ 1.45 per VOR share on Oct 30, 2026, beating analysts' expectations by
| Report Date | Oct 30, 2026 |
|---|---|
| Forecasted EPS | -$ 1.08 |
| Earnings Per Share (Surprise) | -$ 1.45 (-$ 0.37) |
| Last Year's EPS | -$ 66.76 |
| EPS YoY Change |
Out of the last 33 earnings reporting periods, Vor Biopharma beat analysts’ expectations 6 times and fell short of expectations 19 time(s). Vor Biopharma reported earnings per share of -$ 1.45 in the last report falling to reach an estimated EPS of -$ 1.08 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Oct 30, 2026 | -$ 1.08 | -$ 1.45 | -$ 121.63 | |
| Aug 11, 2026 | -$ 0.70 | -$ 1.16 | -$ 251.20 | |
| May 13, 2026 | -$ 0.75 | -$ 0.73 | -$ 5.20 | |
| Mar 30, 2026 | -$ 1.14 | $ 44.50 | -$ 0.26 | |
| Nov 13, 2025 | -$ 3.06 | -$ 121.63 | -$ 8.80 | |
| Aug 12, 2025 | -$ 11.40 | -$ 251.20 | -$ 8.00 | |
| May 15, 2025 | -$ 5.00 | -$ 5.20 | -$ 8.20 | |
| May 14, 2025 | -$ 0.25 | -$ 0.26 | -$ 9.00 | |
| Mar 20, 2025 | -$ 0.34 | -$ 8.80 | -$ 7.80 | |
| Nov 7, 2024 | -$ 8.00 | -$ 8.00 | -$ 0.39 | |
| Aug 8, 2024 | -$ 0.42 | -$ 8.20 | -$ 9.80 | |
| May 9, 2024 | -$ 0.38 | -$ 9.00 | -$ 9.00 | |
| Mar 21, 2024 | -$ 0.50 | -$ 7.80 | -$ 0.43 | |
| Mar 20, 2024 | -$ 0.49 | -$ 0.39 | -$ 10.60 | |
| Nov 7, 2023 | -$ 0.50 | -$ 9.80 | -$ 0.63 | |
| Aug 10, 2023 | -$ 0.42 | -$ 9.00 | -$ 0.58 | |
| May 11, 2023 | -$ 0.37 | -$ 0.43 | -$ 12.20 | |
| Mar 23, 2023 | -$ 0.56 | -$ 10.60 | -$ 9.80 | |
| Nov 10, 2022 | -$ 0.59 | -$ 0.63 | -$ 10.00 | |
| Aug 11, 2022 | -$ 0.66 | -$ 0.58 | -$ 10.00 |
Vor Biopharma’s stock was trading at $ 20.91 on Oct 29, 2026 a day before the last earnings report was released.Following the release of the earnings report, VOR’s price decreased to $ 19.25 on Oct 31, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Oct 30, 2026 | -$ 1.45 | $ 20.91 | $ 19.25 | |
| Aug 11, 2026 | -$ 1.16 | $ 23.37 | $ 22.34 | |
| May 13, 2026 | -$ 0.73 | $ 16.47 | $ 15.07 | |
| Mar 30, 2026 | $ 44.50 | $ 14.48 | $ 17.84 | |
| Nov 13, 2025 | -$ 121.63 | $ 10.06 | $ 10.01 | |
| Aug 12, 2025 | -$ 251.20 | $ 39.80 | $ 40.40 | |
| May 15, 2025 | -$ 5.20 | $ 3.42 | $ 3.54 | |
| May 14, 2025 | -$ 0.26 | $ 3.20 | $ 3.42 | |
| Mar 20, 2025 | -$ 8.80 | $ 16.88 | $ 17.40 | |
| Nov 7, 2024 | -$ 8.00 | $ 17.20 | $ 19.16 | |
| Aug 8, 2024 | -$ 8.20 | $ 16.40 | $ 16.40 | |
| May 9, 2024 | -$ 9.00 | $ 37.00 | $ 34.20 | |
| Mar 21, 2024 | -$ 7.80 | $ 36.00 | $ 38.60 | |
| Mar 20, 2024 | -$ 0.39 | $ 36.40 | $ 39.20 | |
| Nov 7, 2023 | -$ 9.80 | $ 36.40 | $ 37.20 | |
| Aug 10, 2023 | -$ 9.00 | $ 52.40 | $ 58.80 | |
| May 11, 2023 | -$ 0.43 | $ 81.80 | $ 86.40 | |
| Mar 23, 2023 | -$ 10.60 | $ 108.60 | $ 117.60 | |
| Nov 10, 2022 | -$ 0.63 | $ 81.60 | $ 83.60 | |
| Aug 11, 2022 | -$ 0.58 | $ 96.00 | $ 108.00 |
Vor Biopharma released its most recent earnings reports in October 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Vor Biopharma missed analysts’ expectations during the last earnings period by
